Ruimei presents three complementary medical-aesthetic products: a human collagen injectable, a lyophilised extracellular vesicle powder and an integrated dual-platform concept. Each is explained through its composition, technical rationale and professional context.
A human-cell-derived Type I collagen injectable developed around structural fidelity. Its collagen profile is characterised through methods including circular dichroism and SDS-PAGE, while the product concept focuses on precise, natural-looking soft-tissue support and overall skin quality. Use is subject to approved indications and local requirements.
A freeze-dried extracellular vesicle preparation designed for controlled storage and professional handling. Lot 20260501 was characterised by NTA, TEM and Western blot, with a reported particle-size result of 121.1 nm and detection of CD63, CD81 and CD9. Intended use must follow the product status in each market.
A dual-platform concept that brings structural collagen and extracellular vesicle science into one coherent view of skin quality. It shows how material structure and cellular communication can inform different aspects of product and protocol design. Application depends on local approval and professional assessment.
Ruimei begins by making the role of each product understandable: what it contains, how it is characterised and which aspect of skin quality it is intended to address. This clarity helps professionals and general visitors read the portfolio without confusing material science with finished-product performance.
Medical-aesthetic products should be used only within their approved scope and by appropriately qualified professionals where required. Product availability, indications and permitted claims vary by market.
HAVE A QUESTION ABOUT RUIMEI, OUR PRODUCTS OR OUR TECHNOLOGIES? LEAVE YOUR DETAILS AND OUR TEAM WILL RESPOND.